# Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

> **NCT01423110** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 14 (actual)

## Conditions studied

- Sporadic Inclusion Body Myositis

## Interventions

- **BIOLOGICAL:** BYM338
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01423110
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01423110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01423110, "Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01423110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*